John Marshall Money Professor, Biomedical Engineering
Bio
B.S. Johns Hopkins University, 1999Ph.D. Massachusetts Institute of Technology, 2005Post-Doc Harvard Medical School, 2005-2008
"My research combines engineering principles with molecular biology to tackle fundamental problems in cancer and infectious disease."
Kevin Janes, Professor
Kevin Janes designs and uses new experimental and computational approaches for analyzing cell signaling and transcriptional networks in cancer and infectious disease. He received his B.S. and B.A. degrees in Biomedical Engineering and Spanish at Johns Hopkins University in 1999. He was a Fulbright Scholar at La Universidad de Santiago de Compostela in Spain before attaining his Ph.D. in Bioengineering at M.I.T. in 2005 under the joint supervision of Douglas Lauffenburger and Michael Yaffe.
Dr. Janes completed a postdoctoral fellowship at Harvard Medical School in the Department of Cell Biology with Joan Brugge and began his faculty position at the University of Virginia in 2008. During that time, Dr. Janes was recognized as a Pew Scholar, a Packard Fellow, a Kavli Fellow, and a recipient of the NIH Director’s New Innovator Award. He is currently an Associate Professor in the Department of Biomedical Engineering at the University of Virginia, the Chair of the Tumor Biochemistry and Endocrinology study section at the American Cancer Society, and a member of the Board of Reviewing Editors for Science Signaling.
Awards
Elected to the College of Fellows of the American Institute for Medical and Biological Engineering2020
Research Interests
Biomedical Data Sciences
Computational Systems Biology
Quantitative Biosciences
Biomedical Data Sciences
Kevin Janes is a professor in the Department of Biomedical Engineering. He designs and uses new experimental and computational approaches for analyzing cell signaling and transcriptional networks in cancer and infectious disease.
Pioneers in Cancer Systems Biology will Establish a Center to Look Deep Inside Cells at the “Little Organs” of Cancer
New research center, funded by the NIH's National Cancer Institute, to leverage UVA's expertise in cancer systems biology and biomedical data sciences.
UVA Engineering’s Kevin Janes Scores Three Articles in a Single Issue of Oncology Journal
When an athlete scores three times in a single game, it's called a hat trick. If scientific research had hat tricks, Janes would have fans screaming in the stands.
Just a handful of universities have multiple members on the 69-person board of the journal Cell Systems, including Harvard, MIT, Princeton, Stanford, UCSF and UVA.
So-called “triple-negative” breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.
Nucleocytoplasmic transport of active HER2 causes fractional escape from the DCIS-like state. Nat Commun, 14, 2110. Wang L*, Paudel BB*, McKnight RA, Janes KA. (2023)
Modeling the complete kinetics of coxsackievirus B3 reveals human determinants of host-cell feedback. Cell Syst, 12, 304-23.e1-e13. Lopacinski AB*, Sweatt AJ*, Smolko CM, Gray-Gaillard E, Borgman CA, Shah M†, Janes KA†. (2021)
Pan-cancer drivers are recurrent transcriptional regulatory heterogeneities in early-stage luminal breast cancer. Cancer Res, 81, 1840-52. Singh S, Sutcliffe MD, Repich K, Atkins KA, Harvey JA, Janes KA. (2021)
Fragmentation of small-cell lung cancer regulatory states in heterotypic microenvironments. Cancer Res, 81, 1853-67. Schaff DL*, Singh S*, Kim K-B, Sutcliffe MD, Park K-S, Janes KA. (2021)
Premalignant oligodendrocyte precursor cells stall in a heterogeneous state of replication stress prior to gliomagenesis. Cancer Res, 81, 1868-82. Sutcliffe MD, Galvao RP, Wang L, Kim J, Singh S, Zong H†, Janes KA†. (2021)
